ESTRO 2024 - Abstract Book

S2599

Clinical - Urology

ESTRO 2024

Overall, 322 patients (39.1%) underwent ADT, according to clinical staging and performance status, with a median duration time of 6 months (IQR 5 – 12, available for 237 patients).

Median follow-up (FU), available for 709 (86%) patients, was 30 months (IQR 17 – 40) with a median PSA (available for 642 pts) of 0.56 ng/ml. A total of 77 patients (9.3%) experienced a BP, with a median time from RT treatment of 26 months (IQR 18 - 41). CP was observed in 63 patients (8.9%) with a median time from the end of RT of 26 months (IQR 18 – 41); the 30.2% (19 patients) was unfavourable intermediate, 28.6% (18 patients) was high/very-high risk, 25.4% (16 patients) was favorable intermediate and 15.9% (10 patients) was low risk group.

Local recurrence was registered for 39,7% (25) of patients; the other reported CPs were 20.6% (13) lymphnodal, 34.9% (22) bone and 3,2% (2) visceral.

At last FU (available for 726 patients (88%)), 14 (2%) patients died for other causes than PCa, 633 (87.2%) are alive with no evidence of disease and 79 (10.8%) are alive with disease.

Considering maximum late toxicities (data available for 507 patients (61.5%)), 46 (9%) and 17 (3,4%) patients experienced late G≥2 GU and GI toxicities, respectively. Toxicities according to CCI -score are reported in Table 2 . No significant association was found for CCI and both maximum late GI and GU toxicities.

Conclusion:

UHRT is a safe and effective treatment. Despite the high presence of comorbidities, these patients have excellent biochemical control and secure GI/GU toxicity profiles. Moreover, CCI score has shown no impact on reported toxicities, thus, UHRT should be proposed as a treatment option in this setting of patients.

Keywords: UHRT PCa Toxicity CCI

2991

Poster Discussion

Rectal bleeding after curative intended radiotherapy for prostate cancer

Ellen L Schaldemose 1 , Lars U Fokdal 1 , Ahmed H Zedan 1 , Lise N Bentzen 1 , Martin Berg 2 , Henrik D Nissen 2 , Bjarke Mortensen 2 , Christine V Madsen 1 1 University Hospital of Southern Denmark, Department of Oncology, Vejle, Denmark. 2 University Hospital of Southern Denmark, Radiotherapy Research Team, Department of Oncology, Vejle, Denmark

Purpose/Objective: